Aventis Files Fresh Patent Suit Against Mylan Over Generic Allegra

Law360, New York (September 6, 2005, 12:00 AM EDT) -- Aventis' patents for the lucrative allergy drug Allegra spawned new litigation last week against Mylan Pharmaceuticals, just as new plans were announced by rivals Barr and Teva to cooperate in manufacturing a generic version of some dosages.

France-based Aventis Pharmaceuticals Inc., which in 1996 launched the drug that generated about $1.4 billion in the past year, is once again taking action to protect six patents for certain dosages of Allegra and Allegra-D against West Virginia-based Mylan.

The complaint, filed in U.S. District Court for the District...
To view the full article, register now.